Fig. 2: Glucosylceramide and sphingomyelin in PD patients with distinct types of GBA variants.

a Glucosylceramide fraction in patients with idiopathic PD and in GBA-PD patients carrying risk variants (RV), mild mutations, and severe mutations. b Sphingomyelin fraction in patients with idiopathic PD and in GBA-PD patients with risk variants (RV), mild mutations, and severe mutations. Unadjusted sphingolipid fractions in CSF of 271 PD patients are shown in box and jitter dot blots.